HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

FDA Adds “Trade Secret Ingredients” Page To Growing Cosmetics Website

This article was originally published in The Rose Sheet

Executive Summary

FDA’s website now includes a page discussing the bearing of trade secrets on cosmetic product labeling, and specifically why fragrance components can be identified generically as “fragrance.” The agency has been expanding its cosmetics web platform actively in 2014, adding information on adverse-event reporting and anti-aging skin treatments, among other subjects.

You may also be interested in...



IFRA Report To EC Addresses Trade Secrets, Dangers Of Full Disclosure

Safeguarding trade secrets “remains the most practical and efficient means of protecting the intangible assets” produced by innovation in the fragrance industry, IFRA asserts in a recently issued report. Threats to the industry’s intellectual property, including calls for full disclosure of formulas, put the market at risk, the group says.

Unilever’s Dove Recommits To ‘Real Women’ Against Rising AI Threat

Unilever PLC’s Dove and Baby Dove brands continue tackling prominent social causes with a vow to be responsible about representing women realistically in advertising in the age of AI and a renewed commitment to closing the Black maternal care gap.

L’Oreal Joins J&J And Major Retailers Defending Benzene Class Actions In Federal Courts

Benzoyl peroxide-based acne drug products and their alleged proclivity to become contaminated with carcinogenic benzene are at the center of putative class actions filing against L’Oreal in federal courts around the US.

Latest Headlines
See All
UsernamePublicRestriction

Register

RS019218

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel